In the News
ADA updates 2021 Standards of Care to address latest research on diagnosis, treatment
The American Diabetes Association (ADA) 2021 Standards of Medical Care in Diabetes now reflect new data on teplizumab and sodium-glucose cotransporter-2 inhibitors, as well as the effects of dapagliflozin and finerenone on patients with chronic kidney disease.
PPIs may have beneficial glycemic effects in patients with diabetes
A systematic review and meta-analysis found that proton-pump inhibitors (PPIs) improved glycemic indices in patients with diabetes and did not appear to affect risk for incident diabetes.
Manufacturer's trials find positive results for combo drug for type 2 diabetes
Tirzepatide, a not-yet-approved dual glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptor agonist, was tested against placebo and semaglutide in recent studies.
MKSAP quiz: Insulin in the ICU
This month's quiz asks readers to evaluate a 67-year-old woman who is transferred to the cardiothoracic ICU after undergoing repair of an abdominal aortic aneurysm. She has a 12-year history of type 2 diabetes mellitus.
Spotlight on diabetes prevalence and control
Diabetes became significantly more common from 1999 to 2018, but control of associated risk factors did not, especially in rural areas of the U.S., according to data from the National Health and Nutrition Examination Survey.
Sotagliflozin linked to more days alive, out of hospital in patients with type 2 diabetes recently hospitalized for heart failure
During a median of nine months of follow-up, daily treatment with 200 to 400 mg/d of the experimental drug was associated with about three more days alive and out of the hospital compared to placebo in an industry-funded randomized trial.
Nearly 50% of older U.S. adults reported taking aspirin preventively
A study of National Health and Nutrition Examination Survey data from 2011 to 2018 found that 46.7% of respondents ages 60 years and older used aspirin for primary or secondary cardiovascular disease prevention and suggested potential overuse in certain groups.
Nearly 1.5 million insulin syringes recalled
Recalled syringes may have graduated markings that are printed incorrectly on the syringe barrel.
Metformin recalled due to nitrosamine impurity
The recall includes two lots of metformin hydrochloride extended-release tablets USP (750 mg) manufactured in India and distributed in the U.S.